Kyriakos Mikellis, @ KEFEA

KEFEA: Re-elected president

Pfizer’s Cyprus Business Manager Kyriakos Mikellis has been re-elected for the next two years as president of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA). 

Mikellis stressed that KEFEA’s priorities in the near future will be the implementation of a viable and effective National Health Scheme in Cyprus and the realisation of European directive and falsified medicines. Jacqueline Anastassiades, Managing Director of Merck Sharp & Dohme (MSD) in Cyprus, was elected as vice president. 

KEFEA, founded in 2006, represents the pharmaceutical industry in Cyprus with the aim to implement a sustainable healthcare system for all Cypriots. It’s members are relevant healthcare stakeholders.

Matthias Baumann, © Noxxon AG

Mologen: Preparing for market launch

Starting in  May, Matthias Baumann will be new Chief Medical Officer of immunotherapy specialist Mologen AG. His primary goal will be preparing Mologen’s DNA cancer therapy lefitolimod for market launch.

Baumann will become a member of the Executive Board and will be responsible for research, preclinical and clinical development, approval and Mologen’s clinical strategy. Until his switch to Mologen, Baumann will continue working as CMO for the biotech German company Noxxon Pharma AG. Prior to joining Noxxon in February 2011, Baumann was Chief Scientific Officer of Focus Clinical Drug Development GmbH and previously active in various research and development positions at Roche and Boehringer Mannheim.

Judith Klimovsky, @ Genmab

Genmab: Pushing for growth

Ex-Novartis Senior VP Judith Klimovsky has joined Copenhagen-based Genmab as Executive Vice President and Chief Development Officer. The appointment is meant to pave the way for the antibody specialist to grow into a global biotech company. 

Klimovsky will be responsible for Genmab’s product development strategy in line with the company's corporate strategy. Most recently, she served as Senior Vice President and Global Head, Oncology Clinical Development, at Novartis. Klimovsky is a haematologist by training with extensive experience in various roles at BMS, Merck and Novartis. 

Klimovsky will be based at the company's Princeton, United States location, whilst travelling regularly to the company's locations in Copenhagen, Denmark and Utrecht, The Netherlands.

Linda Summerton, @ Immodulon

One Nucleus: Seasoned Director

One Nucleus, the Cambridge-based not-for-profit membership organisation for international life science and healthcare companies, announced the appointment of Linda Summerton as a Director. Summerton is Chief Executive of Immodulon and a Senior Partner with TranScrip Partners.

Summerton has over 25 years’ experience in the global pharmaceutical industry in large pharmaceutical companies, small biotechnology companies, private equity ventures and specialist service provider organisations. For 18 years, she worked at AstraZeneca, where she held a variety of roles, most recently Head of Strategy and Portfolio for the Oncology and Infection Therapy Area Management Team. She has a first degree and PhD from Cambridge UK, and held a NATO post-doctoral Fellowship tenured at University of California, San Francisco.

Ken Cunningham, © Abzena

Medherant: Chair for the clinic

University of Warwick spin-out Medherant Ltd has appointed Ken Cunningham as its chair right in time for the company’s move into the clinical development of its novel transdermal drug delivery patch technology. Cunningham is already Chairman of Abzena as well as Non-Executive Director of Verona Pharma plc. 

Between 2006 and 2010, Cunningham was at SkyePharma plc, initially as Chief Operating Officer and subsequently as Chief Executive Officer. He holds a Medical Degree from St Mary's, Imperial College London.

Louise Madden © Applied Photophysics

Applied Photophysics: Risen through the ranks

Applied Photophysics, a provider of systems for the biophysical characterisation of biomolecules, has appointed Louise Madden as Chief Executive Officer. She joined Applied Photophysics in March 2014 as commercial director, before being promoted to chief operating officer in 2015.

Madden holds a BA in law and accountancy from Manchester University. Previously, she was Finance Director at Farfield Group Limited and Global Service Manager at Biolin Scientific AB. Before this, she spent 11 years at KPMG.